

Protect *Sensitive Life* from the torture of Cancer



Imavec⁴⁰⁰

Imatinib 400 mg Tablets

Chronic Myelogenous Leukemia

Acute Lymphoblastic Leukemia

Gastrointestinal Stromal Tumours

- Selective inhibitor of the BCR-ABL tyrosine kinase causative of chronic myeloid leukemia
Drugs Today (Barc). 2002 Sep;38(9):901-13.
- First-line option for all stages of chronic myeloid leukaemia
Drugs. 2007;47(12):250-220.
- Superior to interferon plus Cytarabine as first-line treatment for chronic myeloid leukemia in terms of both efficacy and safety
Drugs Today (Barc). 2002 Sep;38(9):901-13.
- FDA approved for the treatment of patients with advanced GI stromal tumour (GIST)
Drugs. 2003;43(15):113-22; discussion 523-4.
- Improves survival time and delays disease progression for patients with gastrointestinal stromal tumour
J Cell Mol Med. 2010 Jun;14(1-2):42-50.

The high complete cytogenetic remission rates, ranging from 41% to 64% with a 5-year progression-free survival of 69% and a 4-year overall survival of 86%–88% in different international trials with imatinib treatment in chronic phase CML patients resistant or intolerant to interferon- α emphasized its exceptional potency Ther Clin Risk Manag. 2008 Feb; 4(1): 163-167.

Safeguards Health in Agony of Cancer